A first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2373 after single dose administration in healthy male subjects of African ancestry.

Trial Identifier: D6800C00001
Sponsor: AstraZeneca
Collaborator:
Parexel International
NCTID:: NCT04269031
Start Date: February 2020
Primary Completion Date: July 2021
Study Completion Date: July 2021
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
United States of America, MD Brooklyn, MD, United States of America, 21225